The clinical observation is encouraging but early-stage; no quantitative efficacy data (response rates, survival) were disclosed. Monitor for future data readouts from the Phase 2a study and the ongoing Phase III HCC trial, which are the primary value drivers. The company's cash runway and need for additional capital remain key risks.
Price Chart
Executive Summary
Can-Fite BioPharma issued a press release highlighting positive clinical observations from its Phase 2a pancreatic cancer study of namodenoson, including one patient with prolonged disease control (~16 months), and emphasizing the drug's RAS signaling inhibition mechanism alongside ASCO momentum. The filing is a routine clinical update with no new financial data, and the company remains a pre-revenue clinical-stage biotech with a $7M market cap.
Key Facts
- Phase 2a pancreatic cancer study enrollment completed; one patient on therapy for ~16 months.
- Namodenoson inhibits RAS, Wnt/β-catenin, and NF-κB signaling pathways per preclinical data.
- Namodenoson has FDA Orphan Drug Designation for pancreatic cancer.
- No new financial data, revenue, or guidance provided in the filing.
- Company has a history of losses and needs additional capital per risk factors in the 20-F.
Financial Impact
No financial figures reported; pre-revenue clinical-stage company.
Risk Factors
- No quantitative efficacy data released; single-patient anecdote is not statistically meaningful.
- Company has history of losses and requires additional capital to fund operations.
- Clinical-stage biotech with no approved products; regulatory and development risks are high.
- Low market cap ($7M) and limited trading liquidity increase volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063782 |
| Document: ea0293189-6k_canfite.htm | 0001213900-26-063782 |
| Document: 0001213900-26-063782-index-headers.html | 0001213900-26-063782 |
| Document: 0001213900-26-063782-index.html | 0001213900-26-063782 |
| Document: 0001213900-26-063782.txt | 0001213900-26-063782 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | — | $1.65 (−4.07%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers